These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 35662814

  • 21. Enzyme replacement with transferrin receptor-targeted α-L-iduronidase rescues brain pathology in mucopolysaccharidosis I mice.
    Kida S, Koshimura Y, Yoden E, Yoshioka A, Morimoto H, Imakiire A, Tanaka N, Tanaka S, Mori A, Ito J, Inoue A, Yamamoto R, Minami K, Hirato T, Takahashi K, Sonoda H.
    Mol Ther Methods Clin Dev; 2023 Jun 08; 29():439-449. PubMed ID: 37251981
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T, Shimizu H, Fukuda T, Kawagoe S, Matsumoto J, Shimada Y, Kobayashi H, Ida H, Ohashi T, Morimoto H, Hirato T, Nishino K, Eto Y.
    Mol Genet Metab; 2012 Sep 08; 107(1-2):122-8. PubMed ID: 22704483
    [Abstract] [Full Text] [Related]

  • 25. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA, Kimura A.
    Drug Des Devel Ther; 2017 Sep 08; 11():2467-2480. PubMed ID: 28860717
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. A phase I/II study on intracerebroventricular tralesinidase alfa in patients with Sanfilippo syndrome type B.
    Muschol N, Koehn A, von Cossel K, Okur I, Ezgu F, Harmatz P, de Castro Lopez MJ, Couce ML, Lin SP, Batzios S, Cleary M, Solano M, Nestrasil I, Kaufman B, Shaywitz AJ, Maricich SM, Kuca B, Kovalchin J, Zanelli E.
    J Clin Invest; 2023 Jan 17; 133(2):. PubMed ID: 36413418
    [Abstract] [Full Text] [Related]

  • 28. Effect of systemic high dose enzyme replacement therapy on the improvement of CNS defects in a mouse model of mucopolysaccharidosis type II.
    Cho SY, Lee J, Ko AR, Kwak MJ, Kim S, Sohn YB, Park SW, Jin DK.
    Orphanet J Rare Dis; 2015 Oct 31; 10():141. PubMed ID: 26520066
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
    McCarty DM, DiRosario J, Gulaid K, Killedar S, Oosterhof A, van Kuppevelt TH, Martin PT, Fu H.
    Metab Brain Dis; 2011 Mar 31; 26(1):9-19. PubMed ID: 21225451
    [Abstract] [Full Text] [Related]

  • 33. Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats.
    Janson J, Andersson G, Bergquist L, Eriksson M, Folgering JHA.
    Mol Genet Metab Rep; 2020 Mar 31; 22():100554. PubMed ID: 31908953
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. A cDNA analysis disclosed the discordance of genotype-phenotype correlation in a patient with attenuated MPS II and a 76-base deletion in the gene for iduronate-2-sulfatase.
    Fukuhara Y, Miura A, Yamazaki N, So T, Kosuga M, Yanagi K, Kaname T, Yamagata T, Sakuraba H, Okuyama T.
    Mol Genet Metab Rep; 2020 Dec 31; 25():100692. PubMed ID: 33335838
    [Abstract] [Full Text] [Related]

  • 37. Efficient engraftment of genetically modified cells is necessary to ameliorate central nervous system involvement of murine model of mucopolysaccharidosis type II by hematopoietic stem cell targeted gene therapy.
    Miwa S, Watabe AM, Shimada Y, Higuchi T, Kobayashi H, Fukuda T, Kato F, Ida H, Ohashi T.
    Mol Genet Metab; 2020 Aug 31; 130(4):262-273. PubMed ID: 32631737
    [Abstract] [Full Text] [Related]

  • 38. Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA.
    Pericleous K, McIntyre C, Fuller M.
    Mol Genet Metab Rep; 2023 Sep 31; 36():100985. PubMed ID: 37332488
    [Abstract] [Full Text] [Related]

  • 39. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment.
    Mohamed S, He QQ, Singh AA, Ferro V.
    Adv Carbohydr Chem Biochem; 2020 Sep 31; 77():71-117. PubMed ID: 33004112
    [Abstract] [Full Text] [Related]

  • 40. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
    Saville JT, Derrick-Roberts ALK, McIntyre C, Fuller M.
    Hum Gene Ther; 2021 Apr 31; 32(7-8):420-430. PubMed ID: 33339477
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.